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Abstract
Patients treated for lung cancer may develop lung toxicity induced by
chemotherapy (DILD), radiation or combined radiation recall pneumo-
nitis. In the literature, some cases of immune-mediated pneumonitis
have been reported associated with immunotherapy. The clinical and
radiologic features of interstitial lung toxicity are unspecific, dyspnea
and dry cough are the most common symptoms while the most frequent
radiological pattern is the cryptogenic organizing pneumonia (COP).
Why only some individuals treated with these drugs develop interstitial
lung toxicity is unclear. Old age, ethnicity, doses, drug interactions,
oxygen damage and radiation therapy are known risk factors, as well as
pre-existing lung disease. There are no clear indicators of the risk of
developing lung toxicity secondary to drugs or radiation for individual
patients. In the last few years some studies have reported the utility of
KL 6 for the evaluation of DILD. The treatment is based on high doses
of systemic steroids or immune suppressor. In this study we report se-
vere interstitial lung damage in patients treated with different anti-bla-
stic, immune and radiation therapies. Treated with surgery, chemothe-
rapy, immuno- and radiotherapy for lung cancer, they unfortunately
died of severe DILD.
Introduction
More than 350 different pharmacological molecules can provoke
drug-induced respiratory disorders: lung toxicity may involve the
airways, lung parenchyma, mediastinum, pleura, pulmonary vascula-
ture and/or neuromuscular system. The most common manifestation of
drug-induced lung toxicity is drug-induced interstitial lung diseases
(DILD) [1-3]. Drugs frequently associated with the development of dif-
fuse fibrotic diseases (more than 10% of patients exposed develop
DILD) include cytotoxic drugs such as bleomycin, cyclophophamide,
methotrexate and hydroxyurea. Many other drugs can adversely affect
the lung, inducing different types of fibrotic alterations [1]. The prin-
cipal risk factors for the development of DILD include age, sex, genetic
factors, oxygen administration, drug interactions and dosages, radia-
tion and pre-existing lung disorders [3]. In particular, patients treated
for lung cancer may develop lung toxicity as a result of chemotherapy,
radiation or combined therapies (radiation recall pneumonitis). The
panorama of treatment options includes new immunotherapeutic
drugs, approved for lung cancer therapy. These molecules enhance
anti-tumor immunity by inhibiting negative T cell regulators and pro-
grammed cell-death-1 [4-10]. Immune checkpoint inhibitors currently
approved for treatment of advanced NSCLC include nivolumab (anti
CTLA-4 and anti PD1), pembrolizumab (anti PD1) and atezolizumab
(anti PDL-1) [7,8]. Despite encouraging results, these drugs seem as-
sociated with autoimmune-like toxicities, such as pneumonitis, in 
3-10% of cases [9,11,12].
In this study we report three cases of severe interstitial lung damage
in patients treated with different anti-blastic, immune and radiation
therapies. Treated with surgery, chemotherapy, immuno- and radiothe-
rapy for lung cancer, they unfortunately died of severe DILD.
Case 1
The first patient was a 72-year-old male, ex-smoker, with profes-
sional exposure to asbestos as a hairdresser (hairdryers once con-
tained asbestos). In 2014, the patient manifested recurrent pleural ef-
fusion in the left lung, with negative histocytological assay. Two years
later (May 2016) the patient was diagnosed with epitheliomorphic me-
sothelioma and underwent atypical resection of the upper and lower
left lobes, pleural, pericardial, thymic and mediastinal lymph nodes.
The patient underwent four cycles of chemotherapy with carbopla-
tinum-pemetrexed until November 2016 and radiotherapy at 50 Gy in
25 fractions until February 2017. The patient was periodically assessed
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tory infections were excluded and the patient was treated with cPAP,
high-dose systemic steroids and antibiotics. He died of severe rapid
pulmonary fibrotic involvement ten days later.
Case 3
The third patient was a 72-year-old male, ex-smoker, ex electrician,
with COPD, ischemic cardiopathy (treated with stenting in 2009) and
squamous cell laryngeal carcinoma pT1N0 diagnosed in 2011. In Ja-
nuary 2014 he underwent a follow up CT scan of the chest that detected
a nodule in the lingular bronchus with stenosis and atelectasia. A bron-
choscopy with TBNA was performed and squamous cell carcinoma was
identified (lymph node 10 L positive). The total body CT scan was ne-
gative for metastases. PET evaluation revealed increased uptake in the
left para-hilar lung. The patient was in stage IIb (cT2aN1M0) but it was
decided to avoid surgery because of comorbidities; in June 2014 the pa-
tient started chemotherapy (carboplatinum + vinorelbine, four cycles)
and concomitant radiotherapy in the mediastinal area (DTF 66 Gy). To-
lerance was good and a reduction in bronchial stenosis was obtained.
Unfortunately, six months later PET and CT scan showed recurrence of
neoplastic disease in the left hilar area. In June 2015, the patient was
treated with cyberknife radiotherapy but the response was unsatisfac-
tory and compassionate use of Nivolumab was made to improve control
of the disease. The patient started Nivolumab therapy and remained
stable until March 2016, when after the eleventh cycle, CT scan re-
vealed an increase in the left hilar lesion with pleural effusion. In May
he was therefore treated with third line chemotherapy (carboplatinum-
taxotere). After the first cycle, he complained of severe dyspnea and
asthenia; blood gas analysis indicated hypoxemia. CT of the chest do-
cumented bilateral ground glass opacities and interstitial diffuse lung
involvement with NSIP pattern. Infections were excluded by microbio-
logical examination. Based on the radiological features and clinical
symptoms of DILD, the patient was treated with high doses of systemic
steroids. Unfortunately, interstitial involvement was completely refrac-
tory to the treatment (with radiological evidence of progressive deve-
lopment of what seemed to be UIP pattern). Respiratory exchange de-
teriorated sharply and the patient died in February 2017.
Discussion
Drug-induced interstitial lung disease is often implicated in lung
toxicity and is a very heterogeneous group of disorders. The number of
cytotoxic treatments and biological therapies that can cause fibrotic
lung toxicity is increasing and 3% of all cases of interstitial pneumo-
nitis are secondary to exposure to drugs [1,13]. DILD can arise as a di-
rect cytotoxic effect of a specific pharmacological compound or as a
consequence of indirect release of various mediators of tissue damage
(cytokines, chemokines, reactive oxygen species, etc.). Induction of al-
veolitis, pulmonary edema and aberrant fibrotic repair mechanisms
lead to DILD [2]. Another pathogenetic mechanism of DILD may be
oxidative burst and oxidant/antioxidant imbalance [3]. Generally, the
histological and radiological patterns of DILD are unspecific and may
include hypersensitivity pneumonitis, organizing pneumonia, usual in-
terstitial pneumonia, diffuse alveolar damage, non-specific interstitial
pneumonia, granulomatous pneumonitis, bronchiolitis obliterans orga-
nizing pneumonia [1-3].
In patients treated for lung cancer, radiation therapy may also induce
fibrotic pulmonary damage, according to the site and extent of irradia-
tion. It is estimated to occur in 5-10% of patients treated at mediastinal
level and 5-50% of those undergoing lung irradiation [14]. Associative
by oncologists and radiotherapists. Neoplastic disease was stable.
However, in April 2017 the patient developed dry cough, dyspnea and bi-
lateral edema of the legs, followed by respiratory failure and atrial fi-
brillation with concomitant heart failure. Fever was absent and infec-
tions were excluded by microbiological examination. HRCT of the chest
revealed diffuse bilateral ground glass opacities, reticular fibrotic in-
volvement and large areas of parenchymal consolidation (Figure 1). In
the intensive care unit, the patient was treated with NIV/CPAP, optiflow,
antibiotics (cotrimoxazole, piperacillin/tazobactam) and antimycotics
(caspofungin), high dose iv steroids (methylprednisolone 250 mg x 2,
then 125 mg/die) and oral azathioprine (50 mg every 12 h). HRCT of
the chest improved after one week of treatment with a significant re-
duction of ground glass opacities and interstitial involvement. The pa-
tient was transferred to our Pneumology Unit under oxygen therapy
(ventimask FiO2 50-60%), antibiotics and steroids. Azathioprine was
stopped due to a sharp increase in creatinine levels. A few days later,
the patient’s condition deteriorated and HRCT revealed new bilateral
ground glass opacities and areas of consolidation. He died of radiation
recall pneumonitis two weeks later.
Case 2
The second patient was a 63-year-old male, ex-smoker, without pro-
fessional exposure, with severe emphysema, COPD, GER and mono-
clonal gammopathy. He reported a recent increase in dry cough and dy-
spnea. Chest HRCT showed combined emphysema-fibrosis syndrome.
A nodule was also detected in the right upper lobe associated with me-
diastinal lymph node involvement. PET was positive in these patholo-
gical areas and endobronchial ultrasound bronchoscopic biopsy re-
vealed a lung adenocarcinoma TTF1+, EGFR and ALK WT, stage IIIB
(cT2N3M0). After assessment by the multidisciplinary oncology team,
cisplatinum plus gemcitabin therapy was administered from March to
July 2016. In August 2016, PET showed improvement with weak uptake
in the pulmonary and mediastinal areas. Maintenance therapy with
gemcitabin (1 dose every 21 days) was introduced instead of radiothe-
rapy, but in September 2016 the patient was hospitalized in the Emer-
gency Unit with fever and severe respiratory failure. HRCT showed bi-
lateral ground glass opacities and severe progression of the pre-exi-
sting fibrosis-emphysema pattern. Pulmonary embolisms and respira-
pimeEDITRICE
Figure. 1 High resolution CT of the chest revealed diffuse bilateral
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treatment (radiation therapy combined with chemotherapy) may be sy-
nergistic in determining lung toxicity [14,15]. Radiation recall reac-
tion is an inflammatory reaction arising in a previously irradiated area
after application of precipitating agents, usually chemotherapeutic
drugs. If the lungs are involved, radiation recall pneumonitis (RRP)
may occur: radiotherapy presumably causes a permanent change in va-
scular permeability and in stem cells, leading to expression of cy-
tokines that upregulate when a precipitating agent is introduced. Ty-
pical radiological patterns include ground glass opacities, diffuse hazi-
ness, infiltrations and consolidations [1-3,8]. Cases of pneumonitis in
patients treated with immunotherapy after radiotherapy were recently
reported by Shibaki et al.: two patients treated with radiotherapy 2
years earlier, developed pneumonia after four and six months of Nivo-
lumab treatment [8]. In these cases, RRP exactly mapped the irra-
diated field and the interval between the end of radiotherapy and RRP
was two years. In the literature, the time interval ranges from a few
days to 9 months [8,13]; Ding et al. found a median time interval of 95
days [13]. Our third case developed RRP after chemotherapy and nivo-
lumab, but lung involvement was bilateral, beyond the limits of the field
irradiated.
The new immunotherapy molecules interfere with immunological
tolerance mechanisms, inducing a response to lung cancer cells. They
can have extraordinary clinical efficacy, unfortunately not without im-
mune-related toxic effects [10-12]. Most data on the immune-related
adverse effects of these drugs to the lungs comes from clinical trials
conducted in the context of melanoma, NSCLC and renal cell carci-
noma, while data and real-life results from clinical experience are ex-
tremely limited, despite ongoing clinical studies [8-11]. Although ini-
tial safety data has been published in the literature, an international
multicenter clinical trial on 915 patients reported that pneumonitis de-
veloped in 5% of patients, with increased risk of lung toxicity in cases
of combination therapy with anti CTLA-4 and anti PD-1 [8]. The safety
data from this study offered interesting insights into the latency of
onset: respiratory symptoms may occur in the first three months of the-
rapy or up to 10 months after exposure. It is also suggested that rapid
onset of DILD may carry a negative prognosis. The ILD associated with
anti-programmed cell death 1 antibodies were reported by Naidoo et al.
describing in particular the histories of three patients affected by me-
lanoma and treated with nivolumab. A 70-year-old man who was treated
in a trial of nivolumab given sequentially with ipilimumab. He deve-
loped bibasal consolidative areas with reticular and ground-glass opa-
cities. He rapidly deteriorated with a progressive involvement of all the
lungs. A 38-year-old woman treated with nivolumab for 4 months and
developing wide bilateral diffuse ground-glass opacities, consolida-
tions, nodules and traction bronchiectasis [8]. A 58-year-old man de-
veloping NSIP radiological pattern after only 7 weeks of therapy. Other
data is provided by Nishino et al. who found that in a population of 170
patients treated with nivolumab, alone or in combination with other
immune checkpoint inhibitors, 20 patients (11%) developed pneumo-
nitis [7]. The international clinical trials concluded low risk of DILD
after treatment with nivolumab, pembrolizumab and docetaxel [8-12],
but these results will presumably prove to be underestimated after 2
years follow-up.
Why only some individuals treated with these drugs develop intersti-
tial lung toxicity is unclear. Old age, ethnicity, doses, drug interactions,
oxygen damage and radiation therapy are known risk factors, as well as
pre-existing lung diseases [1,3]. There are no clear indicators of the
risk of developing lung toxicity secondary to drugs or radiation for in-
dividual patients. In the last few years some studies have reported the
utility of KL 6 for the evaluation of DILD. KL 6 is typically elevated in
patients with idiopathic interstitial pneumonia and in certain cases of
cancer, and may therefore be useful for evaluating disease activity and
clinical outcome in patients with ILD-IPF: it could predict the likelihood
of radiation pneumonitis or lung toxicity induced by chemotherapy
[15-20]. Recently, a similar predictive role of Surfactant Protein D (SP-
D) for onset of ILD induced by anticancer agents was compared with KL
6 in an interesting case control study [18]. Nakamura et al. also re-
ported that SP-D was associated with worse prognosis and development
of diffuse alveolar damage [18].
Other interesting studies describe the histotypes and the morpholo-
gical and molecular features of lung cancer in patients with pulmonary
fibrosis: in contrast with previous studies, they report a higher percen-
tage of adenocarcinoma in cases with fibrosis having certain molecular
features [5]. Another article described the frequency of EGFR muta-
tion, ALK and ROS1 rearrangement and PDL 1 expression in patients
with fibrosis and lung cancer [19-21]. Although conducted on limited
cohorts, these studies suggest the need for more detailed molecular
characterization of every type of lung fibrosis associated with cancer in
order to define potential therapeutic targets. These findings imply that
similar molecular-immunochemistry studies and biomarkers may be
useful to predict the risk of developing ILD for patients treated for lung
cancer. In our opinion, patients should be monitored closely for toxicity,
which may arise at any stage during treatment.
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